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Abstract
Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to
combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA
project was to assess the prevalence of PDR mutations and their association with virological outcome in the first
year of cART in children.
Methods: HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least
one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance
mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was
defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox
proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and
virology characteristics and calendar period of cART start and initial cART regimen.
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Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years
(2.1–10.1), CD4 cell count 297 cells/mm3 (98–639), and HIV-RNA 5.2 log10copies/mL (4.7–5.7). Of 37 children (7.8 %, 95 %
confidence interval (CI), 5.5–10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the
prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4–23.9).
Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug
prescribed than among those receiving fully active cART: 32.1 % (17.2–54.8) versus 19.4 % (15.9–23.6) (P = 0.095). In
multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional
year (HR 0.88; 95 %CI, 0.82–0.95; P < 0.001).
Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk
of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over
time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of
virological failure.
Keywords: HIV, Children, Pre-treatment drug resistance mutations, Virological failure, First-line combination
antiretroviral therapy
Background
Pre-treatment drug resistance (PDR) mutations have
been demonstrated to be a major reason for virological
failure (VF) after starting combination antiretroviral
treatment (cART) in HIV-infected adults [1–6]. It is
likely that they play a similar role in HIV-infected
children. In vertically infected children, drug resistance
mutations can be present prior to antiretroviral treat-
ment due to the transmission of the resistant virus
(transmitted drug resistance) from mothers [7] or the
emergence of resistance mutations in wild-type virus
transmitted from mothers as a consequence of pressure
of maternal antiretroviral prophylaxis (drugs that have
crossed the placenta and have a long half-life in infants)
or neonatal prophylaxis [8–10].
In vertically infected children, exposure to single-
dose nevirapine given for prevention of mother to
child transmission (PMTCT) is associated with re-
duced efficacy of this drug when used for early treat-
ment [11], and the response has been correlated with
pre-existing resistance mutations [12–14]. Current
treatment guidelines in the United States and Europe
recommend genotypic resistance testing in all anti-
retroviral naive patients, including vertically infected
children, to detect the presence of PDR mutations
and to adapt their first-line treatment accordingly [15,
16]. Several studies have evaluated the prevalence of
PDR mutations among HIV-infected children [6, 17–25];
however, few have determined their effect on virological
response to first-line cART [6, 14, 23].
We assessed the prevalence of PDR mutations and
their association with virological outcome in the first
year of cART in children within a large collaboration of
HIV observational cohort studies (EuroCoord-CHAIN-
PENTA-EPPICC) in Europe and Thailand.
Methods
Study population
This study was conducted under the joint efforts of the
Collaborative HIV and Anti-HIV Drug Resistance Network
(CHAIN) and the EuroCoord network (CASCADE,
COHERE, EuroSIDA and PENTA/EPPICC).
Cohorts participating through the EuroCoord network
submitted defined dataset (patient demographics, use of
cART, CD4 counts and HIV RNA measurements up to
16 months post-cART start, clinical (AIDS and death)
events and genotypic resistance test) to their network-
specific Coordination Centre, using the HIV Cohort
Data Exchange Protocol [26].
Ethics approval was granted by the ethic committees
of each of the participating cohorts according to local
regulations. Written informed consent from participant-
s’parents or legal guardians was obtained by the partici-
pating cohorts according to national legal and ethics
requirements.
Maternal and infant prophylaxis data were not avail-
able for this analysis. Over the period of the study, no
specific PMTCT protocol was recommended in Europe
however some countries had their own PMTCT guide-
lines [27–31]. Practically, most cohorts used NVP or
PI-based highly active antiretroviral therapy as the
standard of care for mothers and 4–6 weeks zidovudine
prophylaxis for infants. Zidovudine (ZDV) monotherapy
with pre-labour caesarean section was an alternative for
pregnant women who did not require treatment for their
disease or in case of low viral load HIV. Threshold of
CD4 varied over time and across countries (200 or 350
cells/mm3) as well as time to start antiretroviral prophy-
laxis. In Thailand national antiretroviral prophylaxis reg-
imens have evolved from ZDV monotherapy for mothers
and infants in 2000 to ZDV monotherapy plus single
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dose nevirapine (SD-NVP) in 2004 then to NVP-based
cART for women with CD4 < 200 cells/mm3 or ZDV/SD-
NVP for women with CD4 > 200 cells/mm3 with a 7-day
post-partum tail regimen of ZDV/lamivudine to prevent
NVP resistance in SD-NVP exposed women [32].
HIV-infected children aged <18 years were included in
this study if they started cART between January 1,1998,
and December 31, 2008 and if they had ≥1 sample for a
genotypic test taken before the initiation of cART,
whereby cART was defined as receiving at least three
antiretroviral drugs. Genotypic resistance tests could
have been performed retrospectively at each virology lab,
i.e. test results may not necessarily have been used to
guide first-line treatment. HIV genotyping assays were
based on population sequencing techniques. We ob-
tained nucleotide sequences for 93 % and amino-acid
sequences for 7 % of the children. Alignment of nucleo-
tide sequences was done centrally at the Copenhagen
regional coordinating centre. If more than one genotypic
test result was available mutations were cumulated.
Statistical analyses
Definition of PDR mutations and resistance
PDR mutations and resistance were defined in two steps.
First, the World Health Organization 2009 list of NRTI,
NNRTI and PI mutations for the surveillance of trans-
mitted drug resistant HIV strains [33] was used to iden-
tify PDR mutations and distinguish children harbouring
a virus with ≥1 PDR mutations and those harbouring a
virus with no PDR mutation, referred to as ‘no PDR’.
Second, for children harbouring a virus with ≥1 PDR
mutations, the Stanford algorithm version 6.0.5 [34] was
used to classify children into 2 groups: children receiving
fully active cART (Stanford levels 1 and 2, corresponding
to susceptible and potential low-level resistance, for all
prescribed drugs) and those harbouring resistant HIV
strain (Stanford levels 3 4, 5 corresponding to low-level,
intermediate and high-level resistance, respectively)
affecting ≥1 of the prescribed drugs. Among children
with PDR mutations, those receiving fully active cART
were referred to as ‘PDR and fully-active cART’ and chil-
dren with a resistant strain were referred to ‘PDR and
resistant’. Children with PDR receiving a fully active
cART were regrouped with children harbouring a virus
without PDR for the analysis of virological failure
because there was no event among those receiving a
fully active cART. Thus, two groups were considered:
one group including all children with no PDR or ‘PDR
and fully-active cART’ and one group including all children
‘PDR and resistant’.
Virological response
Virological failure was defined as the first of two con-
secutive viral loads >500 copies/mL after 6 months of
cART (window 6–16 months), considering the date of
first viral load >500 copies/mL as failure date. Children
were censored if they died, stopped cART or were lost-
to-follow-up. The time to virological failure was de-
scribed by Kaplan-Meier curves and analysed by Cox
proportional Hazards models. Baseline is defined as date
of cART initiation.
All multivariable models were adjusted for the follow-
ing potential confounders chosen a priori: sex, age, pre-
treatment viral load (log10 transformed) and CD4 count,
subtype (B, non B, unknown), region of origin (African,
European, Asian, other/unknown), year of treatment
start (1998–1999, 2000–2002, 2003–2004, 2005–2006,
2007–2008), previous AIDS diagnosis (yes, no, unknown)
and HIV transmission risk group (vertical, heterosexual,
injection drug use, other/unknown) and initial cART regi-
men (NNRTI plus ≥ 2NRTIs, boosted PI plus ≥ 2NRTIs,
unboosted PI plus ≥ 2NRTIs, other). We conducted a
stratified analysis according to initial cART regimen
(NNRTI plus ≥ 2NRTIs, unboosted PI plus ≥ 2NRTIs).
Proportionality assumptions were checked graphically by
depicting the (log-log (Survival Probability) according to
log(survival time) and by testing an interaction term
between the covariables and the survival time. Analyses
were performed using SAS 9.2 and 9.3 (SAS Institute, Inc.,
Cary, NC). P < 0.05 was considered significant.
Posteriori power calculation
Based on the number of virological failures observed
among the 476 HIV-infected children, we could achieve
90 % power in a two-sided test with type I error of 5 %
to detect a hazard ratio (HR) of 1.95 if risk groups were
well balanced (i.e. 50 % of patients with high risk and
50 % with low risk). The HR limit would be 2.17, 3.05
and 4.64 if risk groups were not balanced whatever the
direction (25–75, 10–90 and 5–95 % respectively) [35].
Results
Study population and baseline characteristics
A total of 476 children had sufficient follow-up and
resistance data to be included in the analysis. They were
enrolled in 18 cohort studies in 11 countries. At base-
line, 246 children (51.7 %) were female and a large
majority was infected through vertical transmission of
HIV (Table 1). The median age at cART initiation was
6.6 years (interquartile range (IQR), 2.1–10.1), median
baseline CD4 cell count 297 cells/mm3 (IQR, 98–639),
and median HIV RNA load 5.2 log10 copies/mL (IQR,
4.7–5.7) (Table 1).
Two hundred thirty two (48.7 %) children initiated
cART with 2 nucleoside reverse transcriptase inhibitors
(NRTIs) and 1 nonnucleoside reverse transcriptase
inhibitor (NNRTI) and 41 (8.6 %) with 3 NRTIs and 1
NNRTI, 139 (29.2 %) with 2 or more NRTIs and 1
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unboosted protease inhibitor (PI) (mostly nelfinavir),
43 (9 %) with 2 or more NRTIs and 1 boosted PI,
and 21 (4.8 %) with other combinations of three or
more drugs (Table 1).
Pre-treatment resistance mutations
At least one PDR mutation was identified in 37 chil-
dren (7.8 %; 95%CI, 5.5–10.6) of whom 76 % har-
bored a virus with NRTI, 46 % with NNRTI and 8 %
with PI resistance mutations and 30 % had PDR
mutations to 2 ARV classes (Table 2). The proportion
of children with PDR mutations was higher among
children below 2 years of age than among those aged
2 years or more; 12.2 % (14 of 155) versus vs 6.4 %
(23 of 361) (P = 0.043).
Of these 37 children, seven were in the ‘PDR and
fully-active cART’ group and 30 children in the ‘PDR
and resistant’ group. In this latter group, 11 children had
PDR mutations to 2 antiretroviral drug classes (Table 2).
Prevalence of PDR mutations was 7.1, 7.7, 7.8 and 9.8 %
in children from African, European, Asian or unknown
origin. There was no statistical difference of PDR
according the geographic origin (P = 0.93). Furthermore,
baseline characteristics were not different between
children with and without PDR mutations (Additional
file 1: Table S1).
Table 1 Characteristics at cART initiation
Characteristics Number Percent
Sex Female 246 51.7
Age years median
(IQR)
6 (2 ; 10)
Age (years) <2 115 24.2
2–5 113 23.7
6–12 197 41.4
13–17 51 10.7
Region of origin Africa 113 23.7
Asia 194 40.8
Europe 118 24.8
Other/unknown 51 10.7
Transmission risk
group
Vertical 419 88.0
IDU 1 0.2
Heterosexual 12 2.5
Other/unknown 44 9.2
Previous AIDS
diagnosis
Yes 99 20.8
No 375 78.8
Unknown 2 0.4
Pretreatment CD4
cell count (/mm3)
median (IQR)*
364 (294;
422)
Pretreatment CD4
cell count (/mm3)*
<200 156 37.9
≥200 and < 350 77 19.2
≥350 and <500 41 10.0
≥500 138 33.5
Pretreatment HIV
RNA (log10 copies/mL)
median (IQR)**
5.2 (4.7; 5.7)
Pretreatment HIV
RNA (log10 copies/mL)**
<4 36 8
≥4 and <5 137 30.5
≥5 and <6 214 47.7
>6 62 13.8
HIV subtype Non B 382 80.3
B 63 13.2
Unknown 31 6.5
Year of cART start 1998–1999 105 22.1
2000–2002 57 12.0
2003–2004 112 23.5
2005–2006 149 31.3
2007–2008 53 11.1
Antiretroviral drug
combination
NNRTI plus≥ 2NRTIsa 273 57.4
Table 1 Characteristics at cART initiation (Continued)
Unboosted PI plus≥
2NRTIsb
139 29.2
Boosted PI plus≥ 2NRTIsc 43 9.0
Otherd 21 4.4
aIncludes 232 who received 2 NRTIs and 41 who received 3 NRTIs. Overall, 184
were on efavirenz and 89 on nevirapine
bIncludes 136 who received 2 NRTIs and 1 each who received 3, 4, and 5
NRTIs. 131 were on nelfinavir, 3 on indinavir, and 2 on ritonavir
cIncludes 37 who received 2 NRTIs, 5 who received 3 NRTIs, and 1 who
received 4 NRTIs. 32 were on lopinavir/ritonavir, 5 on fosamprenavir/ritonavir,
4 on indinavir/ritonavir, and one each on atazanavir or saquinavir
with ritonavir
dIncludes 10 who received (1 NNRTI plus ≥ 2NRTIs plus 1 PI or 1 boosted PI), 5
who received (2NNRTIs plus ≥ 2NRTIs), 4 who received (≥1 NRTI plus 2 PI/
boosted PI), 1 who received (1 NRTI plus boosted PI plus integrase inhibitor
plus fusion inhibitor), and 1 who received (1 NRTI plus 1 boosted PI plus 1
fusion inhibitor). *CD4 cell count measurements at cART initiation were
available for 412 children. **Viral load measurements at cART initiation were
available for 449 children
Table 2 Prevalence of resistance mutations using the WHO 2009
list for surveillance of transmitted drug resistance mutations
Number Percent 95 % CI
At least 1 resistance mutation 37 7.8 5.5–10.6
≥ 1 NRTI resistance mutation 28 5.9 3.9–8.4
≥ 1 NNRTI resistance mutation 17 3.6 2.1–5.7
≥ 1 PI resistance mutation 3 0.6 0.1–1.8
Resistance mutations to 2 ARV classes 11 2.3 1.2–4.1
Resistance mutations to 3 ARV classes 0 0
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Analysis of virological failure and risk factors
Overall, median follow-up was 12 months (10; 14) corre-
sponding to 449 person years (PY) of follow-up; children
with fully active treatment were followed-up over a
median of 12 (10; 14) months (424 PY of follow-up), and
children with PDR and receiving a treatment to which
the virus was resistant were followed over a median of
11 (8; 13) months (26 PY of follow-up). Median number
of viral load measurements after baseline was 4 (IQR: 2;
8) and there was no difference in median viral load mea-
surements between the group no PDR/PDR susceptible
and the group PDR and resistant with 4 (2;8) and 4 (2;7)
measurements, respectively. Virological failure occurred
in 83 of 446 children who started with fully active cART
(no PDR or having “PDR and fully-active cART”) and in
9 of 30 children of the “PDR and resistant” group. The
overall estimated cumulative Kaplan-Meier risk of
virological failure at 12 months of cART was 19.8 %
(95%CI, 16.4–23.9). Children in the ‘PDR and resistant’
group tended to have higher cumulative risk of viro-
logical failure than those with no PDR or having ‘PDR
and fully-active cART’, at 32.1 % (17.2–54.8) versus
19.4 % (15.9–23.6) (p = 0.095) (Fig. 1). Crude incidence
rates of virological failure were 35 per 100 PY of follow-
up in the ‘PDR and resistant’ group compared to 19 per
100 PY of follow-up in the no PDR/‘PDR and fully active
cART’ group.
In univariable analysis, younger age, year at cART ini-
tiation (1998–1999 vs 2007–2008), initial cART regimen
(Unboosted PI plus ≥ 2NRTIs vs NNRTI plus ≥ 2NRTIs)
and region of origin (African vs Europe) were signifi-
cantly associated with VF (Table 3). PDR and resistance
to ≥ 1 prescribed antiretroviral drugs was not signifi-
cantly associated with a higher risk of virological
failure in univariable analysis (HR, 1.78; 95 % CI,
0.89–3.54; P = 0.101) and also after adjustment for covari-
ables (aHR, 1.42; 95 % CI, 0.62–3.24; P = 0.400).
Upon multivariable analysis, age remained associated
with VF and the risk of VF decreased by 12 % per year
older at cART initiation (HR 0.88; 95 %CI, 0.82–0.95;
P < 0.001). The association between initial cART regi-
men and virological failure persisted in the multivariable
model. In stratified analysis according to the initial treat-
ment regimen, the association between PDR and resist-
ance to ≥ 1 prescribed antiretroviral drugs was not
significantly associated with a higher risk of virological
failure neither in the > =2NRTI + 1NNRTI stratum nor
in > =2NRTIs + an unboosted PIs stratum (Additional file
2: Figure S1).
Discussion
In this large international pediatric multicohort analysis,
the prevalence of PDR mutations in antiretroviral naïve
children was 7.8 % (95 %CI, 5.5–10.6) and was similar to
that reported in a large European multicohort study,
9.5 % (95 % CI, 8.9–10.1) of 10,056 patients, mostly
adults [6]. Most of mutations were associated with
resistance to NRTIs and NNRTIs reflecting the drug
classes used over that period. Other studies conducted
in different settings with smaller population size re-
ported a frequency of drug resistance mutations ranging
between 5.7 and 100 % depending on the age of children
at time of testing, the birth period and the genotyping
technique sensitivity [7, 9, 10, 12, 17–25].
Cumulative incidence of virological failure tended to
be higher among children starting cART with PDR and
resistance ≥1 drug prescribed than among those starting
with a fully active regimen (Log-rank test: P = 0.095) but
no direct association between PDR mutations and VF
was found, in contrast to what was reported in the large
European multicohort study [6]. This may be a conse-
quence of the smaller sample size of our population and
the relatively low prevalence of PDR mutations. Based
on our population, we could achieve 75 % power to
detect a HR of 3.13 [35]. Another possible reason may
have been the long time interval (6 years or more in over
half the population) between perinatal infection and the
onset of treatment. In this study, higher frequency of
PDR mutations was indeed observed in children less
than 2 years. During this interval, minor populations of
drug-resistant virus, in particular populations that might
emerge following maternal or neonatal prophylaxis with
either zidovudine as monotherapy or single-dose nevira-
pine, might have diminished or disappeared altogether,
so that individuals with minor resistant variants might
have been categorized as entirely without mutations
[12, 36, 37]. Indeed high-sensitivity methods for measure-
ment of drug resistance were not used in this study. How-
ever the usefulness of using high-sensitivity methods over
consensus sequencing to predict virological failure in
children is unclear [12, 13].
High virological failure rates on first-line cART have
been reported in children in different settings [17, 38–42],
including within clinical trials [11, 43, 44]. Among inde-
pendent predictors of virological failure identified were
use of nevirapine vs efavirenz or ritonavir [41, 43–46],
poor adherence to ART [47], prior exposure to single dose
of nevirapine presence of baseline resistance [12, 14], and
younger age [39]. In our study VF was more likely to
occur when cART was started at younger ages (HR 0.88).
This association of outcome with age is probably due to
several factors. Treatment of younger children during the
decade that ARVs were started depended heavily on liquid
forms of ARVs that, particularly for the more potent
protease inhibitors, are often unpalatable. Also during the
time of this study information about the pharmacokinetics
of several important drugs, particularly nevirapine and
nelfinavir, was limited in children aged less than 2 years
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Fig. 1 Kaplan-Meier estimate for proportion of children with virological failure. Risk of failure in children harboring virus fully “susceptible” to cART
(black continuous line) versus risk of failure in children with virus “resistant” to at least one drug (red continuous line) (Log-rank test: P = 0.0954).
The dotted lines correspond to 95 % confidence intervals. In total, 21 patients stopped cART between cART initiation and 6 months of follow-up
and were censored at cART stop. This explains why at 6 months there are 427 participants at risk in the no PDR/PDR and susceptible group and
28 participants at risk in the PDR and resistant group
Table 3 Univariable and multivariable analysis of risk factors for virological failure
Univariable Analysis Multivariable Analysis
HR (95 % CI) P Global P aHR (95 % CI) P Global P
PDR resistant vs no PDR/susceptible 1.78 (0.89–3.54) 0.101 1.42 (0.62–3.24) 0.400
Sex (male vs female) 1.06 (0.71–1.60) 0.770 1.45 (0.91–2.31) 0.117
Age (per additional year) 0.89 (0.84–0.93) 0.000 0.88 (0.82–0.95) 0.0005
Origin (ref Europe) 0.029 0.720
Africa 0.40 (0.20–0.78) 0.008 1.14 (0.49–2.62) 0.759
Asia 0.73 (0.45–1.18) 0.197 1.02 (0.464–2.25) 0.960
Other/unknown 1.10 (0.58–2.09) 0.764 0.65 (0.28–1.50) 0.313
Previous AIDS diagnosis (yes vs no) 1.18 (0.73–1.91) 0.495 1.00 (0.56–1.76) 0.986
Pretreatment CD4 count (per 100 cells/mm3) 1.01 (0.98–1.04) 0.510 0.96 (0.92–1.00) 0.048
Pretreatment viral load (per 1 log10 copies/mL increase) 1.16 (0.90–1.50) 0.254 0.99 (0.76–1.28) 0.987
Subtype (non B vs B) 0.85 (0.48–1.50) 0.569 0.70 (0.34–1.45) 0.335
Year of treatment start (ref: 2007–2008) 0.018 0.818
1998–1999 3.14 (1.22–8.07) 0.018 1.11 (0.25–4.95) 0.891
2000–2002 2.01 (0.71–5.70) 0.190 1.89 (0.48–7.40) 0.361
2003–2004 1.97 (0.75–5.21) 0.170 1.29 (0.34–4.96) 0.710
2005–2006 1.36 (0.52–3.60) 0.532 1.27 (0.34–4.79) 0.7230
Antiretroviral drug combination (ref: NNRTI plus≥ 2NRTIs) 0.0002 0.007
Unboosted PI plus≥ 2NRTIs 19.5 (2.68; 1.73) <0.001 3.65 (1.65; 8.05) 0.001
Boosted PI plus≥ 2NRTIs 1.26 (0.56; 2.83) 0.572 1.79 (0.76; 4.57) 0.222
Other 1.73 (0.62; 4.85) 0.300 2.65 (0.90; 7.81) 0.077
All multivariable models were adjusted for sex, age, pre-treatment viral load (log10 transformed) and CD4 count, subtype (B, non B, unknown), region of origin
(African, European, Asian, other/unknown), year of treatment start (1998–1999, 2000–2002, 2003–2004, 2005–2006), previous AIDS diagnosis (yes, no, unknown)
and HIV transmission risk group (heterosexual, injection drug use, perinatal, other/unknown), initial antiretroviral drug combination
HR hazard ratio
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and required dose adjustment [48, 49]. Fixed drug combi-
nations suitable for children were not available during the
period of this study, so large pill burdens or unpalatable
liquid formulations [50] were a common problem in
pediatrics [51–54]. For those reasons, adherence and there-
fore efficacy of cART were often low. The risk of virological
failure is correlated with the proportion of missed doses,
but impact of nonadherence on viral resistance depends on
pharmacology (regimen potency, pharmacokinetics, drug
interactions) and viral (viral fitness, and resistance barrier
to ARV) factors. Suboptimal or poor adherence (missed/
late doses) to drugs can result in sub-therapeutic plasma
concentrations of drugs and subsequent development of
drug resistance to one or more drugs in a given regimen,
and possibly cross-resistance to other drugs of the same
class. In the absence of drug pressure as in treatment inter-
ruptions or discontinuations, resistance mutations are
unlikely to be selected.
Initial cART regimen was significantly associated with
virological failure, however these results should be inter-
preted with caution as children were not randomized to
initial treatment and thus results may be subject of
indication bias, e.g. children with more advanced disease
status (higher proportion of children with a previous
AIDS diagnosis) were more likely to receive boosted PI
regimen.
Our findings of higher risk of VF in younger children
support the 2013 WHO recommendation to treat all
children <3 years of age with boosted-PI [27]. In
addition, due to the higher barrier to drug resistance of
boosted PIs the effect of PDR might be of limited
importance today for clinical practice. Nevertheless pre-
existing NNRTI resistance may still compromise
response to PI-based first line cART. Indeed PI resist-
ance can emerge in children with PDR as evidenced by
the presence of multidrug resistance mutations in single
HIV genome in children failing PI-based first line [55].
Our study has some limitations. It was an observa-
tional study and some resistance results were obtained
retrospectively. However, all children starting cART with
a sample for HIV genotypic resistance testing were
included in the analysis and testing was performed with
no knowledge of the outcome. Association of outcome
with age may be different at the era of WHO PMTCT
option B+. Indeed, in that context more pregnant
women receive NNRTI-based cART and children who
may become infected with resistant virus selected during
treatment failure may have NNRTI resistance mutations
that can persist longer than those selected by single
dose-nevirapine. Another limitation is that we were not
able to assess the effect of the pretreatment CD4
percentage since this was measured in only 49 % of chil-
dren and to address adherence and specific HIV
subtypes effect. Lastly, despite the large study population
it was not possible to specifically analyze more substrata
as the power was already limited for the overall question
of this analysis.
Conclusions
Our study shows that the risk of VF decreased with age
at treatment initiation. We hypothesize that this finding
might be due to fading of PDR mutations over time
although the direct association between those resistance
mutations and VF did not reach statistical significance
potentially due to lack of power. Furthermore, misclassi-
fication due to the relatively low sensitivity of population
sequencing in detecting mutations in viral subpopula-
tions long after initial infection or exposure to ARVs for
the prevention of mother to child transmission shortly
prior to infection could have occurred diluting the effect.
Also, lack of appropriate formulations, in particular for
the younger age group, which may possibly have resulted
in poorer adherence, might be an important determinant
of virological failure.
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